Greenwich LifeSciences (GLSI) announced the expansion of its FLAMINGO-01 clinical trial, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, to Portugal. The company’s application to European regulators has been formally approved, adding Portugal as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania, Ireland, and the US. Breast cancer is the leading cause of death from cancer in women in Portugal with 2,211 deaths in 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLSI:
- Greenwich LifeSciences expands Phase 3 Flamingo-01 clinical trial to Ireland
- Greenwich LifeSciences granted Fast Track designation for GLSI-100 by FDA
- Greenwich LifeSciences initiated with an Outperform at Noble Capital
- Greenwich LifeSciences to build out internal clinical trial operations team
- Greenwich LifeSciences announces expansion of Flamingo-01 into Romania